Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

25.69 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback. 
Via Benzinga
The 3 Things That Matter for Viking Therapeutics Now
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
The biopharmaceutical company has an exciting lead compound in development. 
Via The Motley Fool
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
Earnings Scheduled For July 23, 2025
 
Via Benzinga
A Look Ahead: Viking Therapeutics's Earnings Forecast
 
Via Benzinga
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns. 
Via The Motley Fool
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
Is Viking Therapeutics the Next Big Biotech Bet?
Via The Motley Fool
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Viking Therapeutics Posts Wider Q2 Loss
Via The Motley Fool
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates
Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter. 
Via Benzinga
Viking (VKTX) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading
Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges. 
Via Chartmill
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
The Best Stocks to Invest $1,000 In Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.